IMR Press / EJGO / Volume 40 / Issue 5 / DOI: 10.12892/ejgo4604.2019
Open Access Original Research
Low-risk gestational trophoblastic neoplastic outcome after primary treatment with low-dose methotrexate from 2005 to 2017
Show Less
1 Department of Obstetrics and Gynecology, Anhui Provincial Hospital, Anhui Medical University, Hefei, Anhui, China
2 Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences, Beijing, China

†Contributed equally.

Eur. J. Gynaecol. Oncol. 2019, 40(5), 770–774;
Published: 10 October 2019

Purpose: To retrospectively assess the efficacy and toxicity of single-agent methotrexate (MTX) regimen applied to patients treated in Anhui provincial hospital with low-risk gestational trophoblastic neoplasia (LR-GTN). Materials and Methods: Between 2005 and 2017, on the basis of International Federation of Gynecology and Obstetrics (FIGO 2000) criteria for staging and scoring system, 66 patients with LR-GTN were treated with single-agent MTX. The authors describe their clinical characteristics, resistance/remission/recurrence rates, and treatment toxicity. Results: All patients achieved remission and maintained disease-free status until the moment of analysis. The five-day MTX protocol can achieve a 63.6% remission rate. Resistance to this regimen was obviously related with age and higher pre-treatment hCG. Severe blood toxicity (grade 3 or 4) was shown in four (6.1%) of 66 cases, of which one (1.5%) case was grade 4. Conclusions: For patients diagnosed with LR-GTN, a five-day MTX regimen is an appropriate treatment associating a low rate of toxicity to a high rate of remission.

2000 International Federation of Gynecology and Obstetrics scoring
Low-risk gestational trophoblastic neoplasia
Figure 1.
Back to top